Petrina Kamya, Ph.D., is the Head of AI Platforms and President of Insilico Medicine Canada, overseeing Insilico's end-to-end generative AI-driven drug discovery platform, Pharma.AI, which includes target discovery (PandaOmics), small molecule generation (Chemistry42), and clinical trial outcomes prediction (inClinico). Prior to joining Insilico, Dr. Kamya was at Chemical Computing Group, where she led sales and business development of molecular modeling software for pharma and biotech companies, and then Certara, where she consulted for pharma companies. She holds a BS in biochemistry and a Ph.D. in chemistry.
.svg)
